Chemotherapy-induced immunogenic cell death in combination with ICIs: a brief review of mechanisms, clinical insights, and therapeutic implications.

Front Pharmacol · 2025 · PMC12176807 · PMID 40538545

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a positive trendno p-value reported

While the combination therapy did not meet its primary endpoint for OS, it showed a positive trend toward improvoved PFS and response rates ( Suzuki et al., 2023 ; Kelley et al., 2023 ; Sharma et al., 2024 ; Nakamura et al., 2023 ). 2.3 Triple-negative breast cancer In triple-negative breast cancer (TNBC), the combination of chemotherapy and ICIs has produced encouraging results.

also in 11,005 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.